Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120

Uremic toxins, such as indoxyl sulfate (IS) and p-cresol, or p-cresyl sulfate (PCS), are markedly accumulated in the organs of chronic kidney disease (CKD) patients. These toxins can induce inflammatory reactions and enhance oxidative stress, prompting glomerular sclerosis and interstitial fibrosis,...

Full description

Bibliographic Details
Main Authors: Wen-Chih Liu, Yasuhiko Tomino, Kuo-Cheng Lu
Format: Article
Language:English
Published: MDPI AG 2018-09-01
Series:Toxins
Subjects:
Online Access:http://www.mdpi.com/2072-6651/10/9/367
_version_ 1828272468464238592
author Wen-Chih Liu
Yasuhiko Tomino
Kuo-Cheng Lu
author_facet Wen-Chih Liu
Yasuhiko Tomino
Kuo-Cheng Lu
author_sort Wen-Chih Liu
collection DOAJ
description Uremic toxins, such as indoxyl sulfate (IS) and p-cresol, or p-cresyl sulfate (PCS), are markedly accumulated in the organs of chronic kidney disease (CKD) patients. These toxins can induce inflammatory reactions and enhance oxidative stress, prompting glomerular sclerosis and interstitial fibrosis, to aggravate the decline of renal function. Consequently, uremic toxins play an important role in the worsening of renal and cardiovascular functions. Furthermore, they destroy the quantity and quality of bone. Oral sorbent AST-120 reduces serum levels of uremic toxins in CKD patients by adsorbing the precursors of IS and PCS generated by amino acid metabolism in the intestine. Accordingly, AST-120 decreases the serum IS levels and reduces the production of reactive oxygen species by endothelial cells, to impede the subsequent oxidative stress. This slows the progression of cardiovascular and renal diseases and improves bone metabolism in CKD patients. Although large-scale studies showed no obvious benefits from adding AST-120 to the standard therapy for CKD patients, subsequent sporadic studies may support its use. This article summarizes the mechanisms of the uremic toxins, IS, and PCS, and discusses the multiple effects of AST-120 in CKD patients.
first_indexed 2024-04-13T06:07:09Z
format Article
id doaj.art-876e10d37a874ed39a2cd87ca42c5e17
institution Directory Open Access Journal
issn 2072-6651
language English
last_indexed 2024-04-13T06:07:09Z
publishDate 2018-09-01
publisher MDPI AG
record_format Article
series Toxins
spelling doaj.art-876e10d37a874ed39a2cd87ca42c5e172022-12-22T02:59:13ZengMDPI AGToxins2072-66512018-09-0110936710.3390/toxins10090367toxins10090367Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120Wen-Chih Liu0Yasuhiko Tomino1Kuo-Cheng Lu2Division of Nephrology, Department of Internal Medicine, Tungs’ Taichung Metro Harbor Hospital, Taichung City 435, TaiwanAsian Pacific Renal Research Promotion Office, Medical Corporation SHOWAKAI, Tokyo 160-0023, JapanDivision of Nephrology, Department of Medicine, Fu-Jen Catholic University Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City 243, TaiwanUremic toxins, such as indoxyl sulfate (IS) and p-cresol, or p-cresyl sulfate (PCS), are markedly accumulated in the organs of chronic kidney disease (CKD) patients. These toxins can induce inflammatory reactions and enhance oxidative stress, prompting glomerular sclerosis and interstitial fibrosis, to aggravate the decline of renal function. Consequently, uremic toxins play an important role in the worsening of renal and cardiovascular functions. Furthermore, they destroy the quantity and quality of bone. Oral sorbent AST-120 reduces serum levels of uremic toxins in CKD patients by adsorbing the precursors of IS and PCS generated by amino acid metabolism in the intestine. Accordingly, AST-120 decreases the serum IS levels and reduces the production of reactive oxygen species by endothelial cells, to impede the subsequent oxidative stress. This slows the progression of cardiovascular and renal diseases and improves bone metabolism in CKD patients. Although large-scale studies showed no obvious benefits from adding AST-120 to the standard therapy for CKD patients, subsequent sporadic studies may support its use. This article summarizes the mechanisms of the uremic toxins, IS, and PCS, and discusses the multiple effects of AST-120 in CKD patients.http://www.mdpi.com/2072-6651/10/9/367uremic toxinindoxyl sulfateuremic toxin adsorbentchronic kidney disease-mineral bone diseasereactive oxygen species
spellingShingle Wen-Chih Liu
Yasuhiko Tomino
Kuo-Cheng Lu
Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120
Toxins
uremic toxin
indoxyl sulfate
uremic toxin adsorbent
chronic kidney disease-mineral bone disease
reactive oxygen species
title Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120
title_full Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120
title_fullStr Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120
title_full_unstemmed Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120
title_short Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120
title_sort impacts of indoxyl sulfate and p cresol sulfate on chronic kidney disease and mitigating effects of ast 120
topic uremic toxin
indoxyl sulfate
uremic toxin adsorbent
chronic kidney disease-mineral bone disease
reactive oxygen species
url http://www.mdpi.com/2072-6651/10/9/367
work_keys_str_mv AT wenchihliu impactsofindoxylsulfateandpcresolsulfateonchronickidneydiseaseandmitigatingeffectsofast120
AT yasuhikotomino impactsofindoxylsulfateandpcresolsulfateonchronickidneydiseaseandmitigatingeffectsofast120
AT kuochenglu impactsofindoxylsulfateandpcresolsulfateonchronickidneydiseaseandmitigatingeffectsofast120